Biohaven reports another trial failure for troriluzole; Cyclica raises C$23M for AI driven discovery platform
→ Four months after Biohaven $BHVN reported that troriluzole flopped in a study for anxiety, the biotech is back
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
